More on Cholesterol Trafficking in the Body!

More on Cholesterol Trafficking in the Body!

Bibliographic Details
Main Authors:	Khawla Al-Musalhi, Devaki R. Nair
Format:	Article
Language:	English
Published:	Oman Medical Specialty Board 2013-03-01
Series:	Oman Medical Journal
Subjects:	Cholesterol PCSK-9.
Online Access:	http://www.omjournal.org/fultext_PDF.aspx?DetailsID=347&type=fultext

Similar Items

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
by: Jeffrey D. Browning, et al.
Published: (2010-11-01)

Asociation of PCSK9 with Low Density Lipoproteins (LDL) in the Regulation of LDL-Cholesterol Levels
by: Sarkar, Samantha Khadija
Published: (2015)

Cholesterol-lowering pattern affects the progression of atherosclerosis in apolipoprotein E deficient mice
by: Yusuke Masuda, et al.
Published: (2016-12-01)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
by: Hayato Tada, et al.
Published: (2020-11-01)

Rôle de PCSK9 et conséquences des chirurgies bariatriques sur le métabolisme intestinal du cholestérol
by: Moreau, François
Published: (2017)

Low-density lipoprotein cholesterol lowering treatment: the current approach
by: Irina Crismaru, et al.
Published: (2020-05-01)

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016-07-01)

Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line
by: Maria Giovanna Lupo, et al.
Published: (2020-02-01)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis
by: Ji Hye Yang, et al.
Published: (2017-11-01)

Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report
by: Junki Morino, et al.
Published: (2020-01-01)

HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW
by: M. G. Bubnova
Published: (2018-07-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
by: Silvano Fasolato, et al.
Published: (2020-09-01)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
by: Jean-Mathieu Berger, et al.
Published: (2017-08-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD)
by: Dyonne Y. Vos, et al.
Published: (2021-08-01)

Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
by: Valentina Spigoni, et al.
Published: (2017-07-01)

<i>Acanthaster planci</i> Inhibits PCSK9 and Lowers Cholesterol Levels in Rats
by: Nurjannatul Naim Kamaruddin, et al.
Published: (2021-08-01)

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
by: Jason S. Troutt, et al.
Published: (2010-02-01)

Is lower better? Is lowest the best?
by: Lale Tokgözoğlu
Published: (2017-04-01)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
by: Malwina Grobelna, et al.
Published: (2019-10-01)

Effect of <it>Porphyromonas gingivalis</it> infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice
by: Miyazawa Haruna, et al.
Published: (2012-09-01)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE−/− Mice
by: Ping Jin, et al.
Published: (2021-10-01)

Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol
by: Francine Sirois, et al.
Published: (2017-03-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
by: Qidi Ying, et al.
Published: (2021-02-01)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
by: Maria Pia Adorni, et al.
Published: (2019-05-01)

Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2021-07-01)

Élucidation et identification des différents interacteurs impliqués dans le mécanisme de régulation du LDLR par la protéine PCSK9
by: Ly, Kévin
Published: (2016)

The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
by: Brian T Emmer, et al.
Published: (2018-09-01)

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2019-12-01)

Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
by: Mba CM, et al.
Published: (2019-12-01)

Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome
by: Huaying Shen, et al.
Published: (2020-01-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

Survival benefit of a low ratio of visceral to subcutaneous adipose tissue depends on LDL clearance versus production in sepsis
by: Joseph G. H. Lee, et al.
Published: (2018-03-01)

Naturally Occurring PCSK9 Inhibitors
by: Maria Pia Adorni, et al.
Published: (2020-05-01)

Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels
by: Chuantao Jiang, et al.
Published: (2018-02-01)

Cannot write session to /tmp/vufind_sessions/sess_t5tomboqej7v598arla5si0sdt